We are inside the 17,000 m2 of the Amuchina plant in Casella where 38 people produces the wide-spectrum disinfectant Amuchina.
Angelini Pharma has acquired the ThermaCare® global business rights from GSK.
Price gouging strongly condemned.
Angelini Pharma has obtained the Top Employers Europe 2020 certification.
Angelini Farmacéutica takes 24 th place in the ranking of the most respected and recognised pharmaceutical companies in Spain.
Caring for Mental Health in a Digital World. Digital goes live at Angelini Pharma. The first Psychiatry Innovation Summit, organized by Angelini, took place on 4-6 December 2019 in
Angelini Pharma’s international Public Affairs
initiative “Headway2020 : A new roadmap in Mental Health” goes public ahead of the 27th
World Mental Health Day at the European Parliament.
With healthcare policies, medical guidelines and not surprisingly prescriptions increasingly under scrutiny from both Health Authorities and budget holders, the goals for healthcare professional communications are rapidly changing.
The acquired products include BoxaGrippal® (ibuprofen/pseudoephedrine) and Heumann, a herbal medicinal group of teas.
Angelini supports Italian Red Cross providing
medicines to people in Venezuela whose lives have been shattered by violence and
Angelini Pharma signed a deal with EUSA
Pharma to be the exclusive distributor of Fotivda (Tivozanib).
The Board of Directors of Angelini Holding
S.p.A., is pleased to announce that Pierluigi Antonelli has been appointed as the new
CEO of Angelini Pharma, effective March 4th, 2019.